Retour sur lavenir.net
   ACKERMANS V.HAAREN 284.800 € (-0,77 %)     AB INBEV 74.680 € (+1,22 %)     ARGENX SE 784.400 € (+0,33 %)     UMICORE 20.820 € (-2,25 %)     VASTNED 29.750 € (+0,34 %)     KBC ANCORA 80.900 € (+0,62 %)     IBA 16.760 € (+0,60 %)     KBC 117.250 € (-0,51 %)     ELIA GROUP 138.500 € (-0,86 %)     WDP 22.520 € (+1,08 %)     HOME INVEST BE. 19.300 € (-0,21 %)     AZELIS GROUP 9.910 € (-0,10 %)     WHAT'S COOKING GP 144.500 € (0,00 %)     EVS 27.700 € (-0,72 %)     SYENSQO 66.800 € (-0,30 %)     BPOST 1.552 € (-0,51 %)     TITAN S.A. 52.500 € (-1,50 %)     MONTEA 67.200 € (+1,66 %)     MELEXIS 76.400 € (-3,41 %)     GIMV 45.150 € (+2,03 %)     SHURGARD 25.750 € (+0,98 %)     CENERGY 23.300 € (-3,80 %)     KINEPOLIS GROUP 36.500 € (+2,38 %)     JENSEN-GROUP 84.200 € (+1,45 %)     ORANGE BELGIUM 21.500 € (0,00 %)     SIPEF 92.900 € (+0,32 %)     CIE BOIS SAUVAGE 302.000 € (0,00 %)     FLUXYS BELGIUM D 19.500 € (+0,26 %)     RETAIL ESTATES 70.100 € (+0,43 %)     ATENOR 1.690 € (-3,43 %)     FAGRON 23.800 € (-0,63 %)     ACCENTIS 0.026 € (-1,89 %)     BEKAERT 39.500 € (-1,86 %)     XIOR 26.700 € (+1,14 %)     WERELDHAVE BELGIUM 52.800 € (+0,76 %)     PROXIMUS 6.085 € (-0,33 %)     D'IETEREN GROUP 170.500 € (-1,73 %)     TINC 11.380 € (0,00 %)     SOFINA 220.200 € (+0,46 %)     ONWARD MEDICAL 2.640 € (+0,96 %)     ECONOCOM GROUP 1.515 € (+1,68 %)     GBL 78.950 € (-0,19 %)     RECTICEL 10.740 € (-1,10 %)     NYXOAH 1.530 € (+3,66 %)     AGEAS 69.750 € (+0,50 %)     AGFA-GEVAERT 0.423 € (-1,40 %)     COFINIMMO 84.500 € (+1,62 %)     CARE PROPERTY INV. 12.600 € (+0,48 %)     LOTUS BAKERIES 11 520.000 € (+0,88 %)     VGP 84.300 € (0,00 %)     VIOHALCO 19.320 € (-0,92 %)     BIOTALYS 3.120 € (-1,58 %)     ONTEX GROUP 2.525 € (+0,20 %)     TUBIZE-FIN 225.400 € (+2,55 %)     VAN DE VELDE 30.200 € (0,00 %)     CAMPINE 218.000 € (+1,87 %)     CMB.TECH 12.500 € (-4,87 %)     DECEUNINCK 2.220 € (0,00 %)     CELYAD ONCOLOGY 0.251 € (+0,40 %)     BREDERODE 104.600 € (+1,36 %)  
   NANOBIOTIX 31.080 € (+3,74 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     TOTALENERGIES 68.360 € (-1,31 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     ADYEN 824.900 € (+0,37 %)     EXAIL TECHNOLOGIES 116.700 € (+25,28 %)     CAPGEMINI 89.680 € (+1,33 %)     SHELL PLC 33.700 € (-1,00 %)     BUREAU VERITAS 26.120 € (+0,66 %)     HERMES INTL 1 626.000 € (+0,77 %)     PHILIPS KON 23.890 € (-0,17 %)     SANOFI 75.070 € (+1,78 %)     ASML HOLDING 1 578.200 € (-0,99 %)     BOLLORE 4.100 € (+0,15 %)     VEOLIA ENVIRON. 36.230 € (+0,22 %)     SMCP 5.015 € (+0,30 %)     FLOW TRADERS 25.580 € (-0,93 %)     ASM INTERNATIONAL 948.000 € (-4,34 %)     AYVENS 11.460 € (-0,87 %)     CSG 12.682 € (+2,69 %)     BE SEMICONDUCTOR 282.700 € (-2,21 %)     SCOR SE 31.980 € (+0,50 %)     STMICROELECTRONICS 62.580 € (-3,81 %)     ESSILORLUXOTTICA 168.650 € (+1,54 %)     CRCAM TOURAINE CCI 138.500 € (-0,93 %)     LISI 66.100 € (-0,15 %)     LVMH 495.750 € (+0,27 %)     BOUYGUES 49.750 € (-0,78 %)     DSM FIRMENICH AG 79.980 € (-0,65 %)     NEXANS 141.100 € (-3,75 %)     STELLANTIS NV 5.024 € (-1,95 %)     THALES 216.500 € (-0,87 %)     UMG 18.355 € (+0,71 %)     NN GROUP 76.320 € (-0,29 %)     AHOLD DEL 35.430 € (+0,85 %)     2CRSI 27.520 € (+8,01 %)     SODEXO 51.250 € (-0,10 %)     SOITEC 114.350 € (+1,87 %)     TKH GROUP 43.620 € (+1,73 %)     LNA SANTE 34.000 € (+3,03 %)     OVH 13.600 € (+1,49 %)     BAM GROEP KON 12.550 € (-1,18 %)     EUROFINS SCIENT. 68.960 € (+1,00 %)     AMG 32.900 € (-1,56 %)     CEGEDIM 11.040 € (-1,43 %)     AALBERTS NV 38.980 € (-1,66 %)     DANONE 72.120 € (+3,06 %)     ALSTOM 15.380 € (-1,94 %)     REXEL 36.860 € (-1,18 %)     RELX 27.440 € (-0,29 %)     HAFFNER ENERGY 0.217 € (-2,25 %)     ERAMET 45.160 € (-1,40 %)     SAINT GOBAIN 80.600 € (-1,42 %)     BNP PARIBAS ACT.A 101.120 € (-1,83 %)     RUBIS 31.540 € (+0,64 %)     JCDECAUX 19.050 € (+1,33 %)     PERNOD RICARD 65.960 € (-0,06 %)     SAVENCIA 66.600 € (0,00 %)     AIRBUS 191.900 € (-1,63 %)     ALTEN 53.400 € (+1,81 %)  
News Réglementées
11/03/2023 16:00

Amongst a Plethora of Books Released Yearly, 3/2. Overhuman by Zhuma Bek Transcends Expectations of Narrative Writing

3/2. Overhuman takes storytelling to the next level as it takes an introspective approach to fiction.

NEW YORK, NY / ACCESSWIRE / March 11, 2023 / As time trickles on and publishing books becomes easier, it's become increasingly harder to compete with the rise in published books in the market, and creative and fresh stories are a dime a dozen. 3/2. Overhuman, written by novice writer Zhuma Bek, despite the competitive nature of this industry, manages to break the mold of traditional storytelling.

Freedom, Saturday, March 11, 2023, Press release picture

The Creative Process

Speaking to the author about the origin of the novel's unique name, "Overhuman or 'Ubermensch' is a concept created by the German philosopher and poet Friedrich Nietzsche. Those dissatisfied with life turn to the idea of other worlds or another life. Overhuman delights in being alive and seizes all that life has to offer. If we enjoy watching sunsets, then why do we fear death?"

The Existential Question

Zhuma Bek explores the meaning of life as the book opens with a conversation between two people at opposite stages of their life, one young and the other old, with the older man forgetting who he is. The author writes about reflecting on one's existence via a series of events that hover between dreams and reality. According to the author, "Life is like a dream or a game. We spend it without being able to discern reality from falsity. It is easy to let ourselves get swept up in what is expected and ever more difficult to stop and ponder what it means to be alive. I aspire to demystify existence."

The book explores themes like family, love loss, and social issues. The author is profoundly knowledgeable and inspired by Greek literature, philosophy, and world history.

The novel examines subjects like war and conflict in reality and within a person's mind. It also talks about evolution and what it means for an individual as opposed to a species as a whole.

Critical Reception

Due to its unique perspective that sets it apart from others in its genre, the book has met with favorable responses. It ranked #1 in Biographical Fiction, #3 in Memoirs and #7 in Coming of Age on Amazon Sales.

Conclusion

There are many coming-of-age novels, but there are few that reconcile physical and spiritual aging. Zhuma Bek aims to delve into topics few dare to approach and create enigmatic fables that hide the truth within them.

3/2. Overhuman is a refreshing read aimed at a wide range of audiences. The book is unfiltered and raw, touching many readers with its candor.

For further queries, please contact the author via the information listed below.

Contact Information

Zhuma Bek
contact@32overhuman.com

SOURCE: Zhuma Bek, author

.

View source version on accesswire.com:
https://www.accesswire.com/743307/Amongst-a-Plethora-of-Books-Released-Yearly-32-Overhuman-by-Zhuma-Bek-Transcends-Expectations-of-Narrative-Writing

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière